Eli Lilly has launched the first human study of its potential antibody treatment for coronavirus.
said on Monday it had started an early-stage trial to test its potential treatment for Covid-19, in the world's first study of an antibody treatment against the disease.
Lilly said its early stage study will assess safety and tolerability in patients hospitalized with Covid-19 and results are anticipated by the end of June. Lilly's treatment is an antibody directed against the spike-shaped protein structures of the virus and is designed to block it from locking on to human cells, thus neutralizing the virus.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly starts human study of potential COVID-19 treatmentEli Lilly and Co said on Monday first set of patients have been dosed in an early-stage trial to test its potential treatment for COVID-19, in the world's first study of an antibody treatment against the disease.
Lire la suite »
Coronavirus live updates: Eli Lilly starts world's first human trial of potential antibody treatmentThe coronavirus has infected more than 6.18 million people around the world as of Monday, killing at least 372,469 people.
Lire la suite »
Stocks making the biggest moves in the premarket: Eli Lilly, Coty, Amazon, Zynga, Delta & moreThe stocks making the biggest moves in premarket trading include Eli Lilly, Coty, Amazon, Zynga, Delta, and more.
Lire la suite »
Coronavirus live updates: Eli Lilly starts world's first human trial of potential antibody treatmentThe coronavirus has infected more than 6.18 million people around the world as of Monday, killing at least 372,469 people.
Lire la suite »
Eli Lilly starts human study of potential COVID-19 treatmentEli Lilly and Co said on Monday first set of patients have been dosed in an early-stage trial to test its potential treatment for COVID-19, in the world's first study of an antibody treatment against the disease.
Lire la suite »